
Can CD123-directed CAR T-cell therapy safely target relapsed or refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)? Results from a phase I trial suggest that CD123-targeted CAR T cells can be administered without the prolonged myeloablation predicted by earlier preclinical studies. While remissions were limited and often short-lived, the findings provide important insights into the safety, feasibility, and future development of CAR T-cell therapy for myeloid malignancies. Read more: ow.ly/3uiw5105URK
















